Silexion Therapeutics Corp (SLXN) - Quarterly EPS earnings growth

Official company branding of Silexion Therapeutics Corp. (SLXN)

Silexion Therapeutics Corp is integrating ESG principles into the development of RNA-based drugs for gastric cancer while strictly adhering to biosafety standards. The trend of quarterly earnings per share growth reflects the asset's dynamics, where the 52.50 level represents the current value. Silexion Therapeutics Corp is cultivating its image as an expert in KRAS mutation suppression, building an innovative R&D pipeline to combat solid tumors ahead of the launch of new clinical phases.

Silexion Therapeutics (SLXN) Earnings per share growth in annualized terms for the last twelve months: for the period 08/17/2024 - 11/18/2026

Analytical breakdowns for Silexion Therapeutics Corp

Fundamental company analysis:Silexion Therapeutics Corp., SLXN
Manufactured product of Silexion Therapeutics Corp

Silexion Therapeutics Corp (SLXN) development of innovative RNA drugs against mutated cancer is reflected in the quarterly growth dynamics of earnings per share, which captures the percentage change in net income per common share relative to the same period last year. This indicator measures the efficiency of capitalizing on clinical successes and the interest of pharma behemoths in an acquisition, allowing investors to differentiate real financial progress from speculative expectations.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc.|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Corbus Pharma CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months CANF (Can-Fite BioPharma, Ltd.)|APRE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kazia (KZIA)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc